Literature DB >> 19434730

Familial retinoblastoma in developing countries.

Guillermo L Chantada1, Ira J Dunkel, Ibrahim Qaddoumi, Celia B G Antoneli, Alegria Totah, Serife Canturk, Ibrahim Nawaiseh, Adriana Fandiño, Imelda Pífano, Gonul Peksayar, Karina Braga Ribeiro, David H Abramson.   

Abstract

BACKGROUND: Although screening for familial retinoblastoma has been shown to be beneficial we suspected that such screening programs may be less than optimal in developing countries (DC).
METHODS: Retrospective cohort study comparing patients with familial retinoblastoma from five centers in DC (Argentina, Brazil, Turkey, Jordan, and Venezuela) versus a reference center in the USA.
RESULTS: Ninety-two (32 from the USA and 60 from DC) patients were included. Forty-one (44.6%) patients avoided enucleation, 42 (45.7%) had 1 eye removed, and 9 (9.8%) underwent bilateral enucleation. Eleven (11.9%) had major pathology risk factors at enucleation. There were no cases of metastatic disease at diagnosis. Detection via screening was significantly less common in DC than in the USA (23.3% vs. 71.8%, P < 0.0001). Patients in DC were diagnosed at a significantly later age and with more advanced intraocular disease that led to increased risk of bilateral enucleation. Patients detected by screening in DC were significantly younger at diagnosis, had less advanced intraocular disease, better ocular preservation rates and survival results than those whose retinoblastoma was not detected via early screening. Five-year pEFS was 0.92 for the patients treated in the USA and 0.81 for the patients in DC (P = 0.42). Seven events occurred (extraocular relapse four in patients from DC and second malignancies in three).
CONCLUSIONS: Patients with familial retinoblastoma are less likely to be diagnosed by screening in DC and had higher morbidity and mortality caused by recurrent extraocular retinoblastoma. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2009        PMID: 19434730     DOI: 10.1002/pbc.21970

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.838


  8 in total

1.  Familial retinoblastoma: fundus screening schedule impact and guideline proposal. A retrospective study.

Authors:  P-R Rothschild; D Lévy; A Savignoni; L Lumbroso-Le Rouic; I Aerts; M Gauthier-Villars; M Esteve; D Bours; L Desjardins; F Doz; C Lévy-Gabriel
Journal:  Eye (Lond)       Date:  2011-09-16       Impact factor: 3.775

2.  Epidemiology and Rb1 gene of retinoblastoma.

Authors:  Jun Yun; Yang Li; Chang-Tai Xu; Bo-Rong Pan
Journal:  Int J Ophthalmol       Date:  2011-02-18       Impact factor: 1.779

3.  Preserving vision in retinoblastoma through early detection and intervention.

Authors:  Sidnei Epelman
Journal:  Curr Oncol Rep       Date:  2012-04       Impact factor: 5.075

Review 4.  Retinoblastoma.

Authors:  Helen Dimaras; Timothy W Corson; David Cobrinik; Abby White; Junyang Zhao; Francis L Munier; David H Abramson; Carol L Shields; Guillermo L Chantada; Festus Njuguna; Brenda L Gallie
Journal:  Nat Rev Dis Primers       Date:  2015-08-27       Impact factor: 52.329

5.  Cancer genetics education in a low- to middle-income country: evaluation of an interactive workshop for clinicians in Kenya.

Authors:  Jessica A Hill; Su Yeon Lee; Lucy Njambi; Timothy W Corson; Helen Dimaras
Journal:  PLoS One       Date:  2015-06-02       Impact factor: 3.240

Review 6.  Neonatal Retinoblastoma.

Authors:  Tero T Kivelä; Theodora Hadjistilianou
Journal:  Asia Pac J Oncol Nurs       Date:  2017 Jul-Sep

7.  Familial Retinoblastoma: Raised Awareness Improves Early Diagnosis and Outcome.

Authors:  Ibrahim Al-Nawaiseh; Aseel Q Ghanem; Yacoub A Yousef
Journal:  J Ophthalmol       Date:  2017-03-02       Impact factor: 1.909

8.  A 20-Year Retrospective Review of Retinoblastoma at Two Tertiary Academic Hospitals in Johannesburg, South Africa.

Authors:  Saadiah Goolam; Hemant Kana; Nicky Welsh; Linda Wainwright; Janet Poole; Ismail Mayet
Journal:  Ocul Oncol Pathol       Date:  2017-11-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.